Bussiere JL - Search Results

1

Safety evaluation of immunomodulatory biopharmaceuticals: can we improve the predictive value of preclinical studies?

Black LE, Green JD, Rener J, Dayan A, Cavagnaro JA, Spindler P, Bussiere JL, Bouchard P, Inoue T, Thomas PT, Essayan DM, Gillett NA, Hart TK, Hastings K, House RV, Latta D, Liminga U, Treacy G, Wierda D. Black LE, et al. Among authors: bussiere jl. Hum Exp Toxicol. 2000 Apr;19(4):205-7. doi: 10.1191/096032700678815855. Hum Exp Toxicol. 2000. PMID: 10918508 No abstract available.

2

Preclinical safety assessment considerations in vaccine development.

Bussiere JL, McCormick GC, Green JD. Bussiere JL, et al. Pharm Biotechnol. 1995;6:61-79. doi: 10.1007/978-1-4615-1823-5_3. Pharm Biotechnol. 1995. PMID: 7551238 Review. No abstract available.

3

Alternative strategies for toxicity testing of species-specific biopharmaceuticals.

Bussiere JL, Martin P, Horner M, Couch J, Flaherty M, Andrews L, Beyer J, Horvath C. Bussiere JL, et al. Int J Toxicol. 2009 May-Jun;28(3):230-53. doi: 10.1177/1091581809337262. Int J Toxicol. 2009. PMID: 19546261 Review.

4

Species selection considerations for preclinical toxicology studies for biotherapeutics.

Bussiere JL. Bussiere JL. Expert Opin Drug Metab Toxicol. 2008 Jul;4(7):871-7. doi: 10.1517/17425255.4.7.871. Expert Opin Drug Metab Toxicol. 2008. PMID: 18624676 Review.

5

Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety.

Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J, Fox JA. Kelley SK, et al. J Pharmacol Exp Ther. 2001 Oct;299(1):31-8. J Pharmacol Exp Ther. 2001. PMID: 11561060

6

Lack of developmental neurotoxicity of MN rgp 120/HIV-1 administered subcutaneously to neonatal rats.

Bussiere JL, Hardy LM, Peterson M, Foss JA, Garman RH, Hoberman AM, Christian MS. Bussiere JL, et al. Toxicol Sci. 1999 Mar;48(1):90-9. doi: 10.1093/toxsci/48.1.90. Toxicol Sci. 1999. PMID: 10330688

7

Developmental and reproductive toxicology studies in nonhuman primates.

Chellman GJ, Bussiere JL, Makori N, Martin PL, Ooshima Y, Weinbauer GF. Chellman GJ, et al. Among authors: bussiere jl. Birth Defects Res B Dev Reprod Toxicol. 2009 Dec;86(6):446-62. doi: 10.1002/bdrb.20216. Birth Defects Res B Dev Reprod Toxicol. 2009. PMID: 20025046 Review.

8

Assessment of menstrual cycle length in cynomolgus monkeys as a female fertility endpoint of a biopharmaceutical in a 6 month toxicity study.

Bussiere JL, Moffat G, Zhou L, Tarlo KS. Bussiere JL, et al. Regul Toxicol Pharmacol. 2013 Aug;66(3):269-78. doi: 10.1016/j.yrtph.2013.05.002. Epub 2013 May 13. Regul Toxicol Pharmacol. 2013. PMID: 23680404

9

Phosphatidylinositol 3-Kinase δ-Specific Inhibitor-Induced Changes in the Ovary and Testis in the Sprague Dawley Rat and Cynomolgus Monkey.

Ishida K, Werner JA, Lafleur M, Wisler J, Wannberg S, Kalanzi J, Bussiere JL, Monticello TM. Ishida K, et al. Among authors: bussiere jl. Int J Toxicol. 2021 Jul-Aug;40(4):344-354. doi: 10.1177/10915818211008175. Epub 2021 Apr 19. Int J Toxicol. 2021. PMID: 33866838

10

Survey results on the use of the tissue cross-reactivity immunohistochemistry assay.

Bussiere JL, Leach MW, Price KD, Mounho BJ, Lightfoot-Dunn R. Bussiere JL, et al. Regul Toxicol Pharmacol. 2011 Apr;59(3):493-502. doi: 10.1016/j.yrtph.2010.09.017. Epub 2010 Oct 14. Regul Toxicol Pharmacol. 2011. PMID: 20951178

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

168 results

Search Page

Filters